This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Progressive multifocal leukoencephalopathy진행성 다초점 백질뇌병증 (진행성다초점백질뇌증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: A81.2 (Progressive multifocal leukoencephalopathy) | Special Copayment Reduction: V282 (severe intractable disease, 10% copayment for 5 years after registration)
B. SynonymsMultifocal leukoencephalopathy NOS, PML, JC virus encephalitis, progressive multifocal leukoencephalopathy
C. Adult onsetPossibility of first onset in adulthood: very high — PML occurs almost exclusively in immunocompromised adults, and the main affected groups are adults with HIV/AIDS, hematologic malignancies, or use of immunosuppressants such as natalizumab and ofatumumab.
1. History1958: first described by Åström, Mancall, and Richardson → 1965: Zu Rhein, viral nucleocapsid discovered → 1971: JC virus isolated → 1984: surge in AIDS patients → 2005: natalizumab-associated PML reported.
2. CausesReactivation of JC polyomavirus (John Cunningham virus, JCPyV). 50–70% of healthy adults carry it latently. With impaired cellular immunity (decreased CD4 T cells, immunosuppressants), the virus reactivates and invades the brain.
3. GeneticsHost genetic susceptibility: HLA-A*02:01 is associated with immune control of JCPyV. Viral side: rearrangement of the JCPyV regulatory region (NCCR) is key to acquiring neurotropism. Not a monogenic disease.
4. General epidemiologyOccurred in about 5% of AIDS patients before ART. Incidence in HIV/AIDS decreased by 80% after ART became widespread. 0.1–0.7/1,000 person-years in multiple sclerosis patients treated with natalizumab. Also occurs with hematologic cancers (lymphoma, leukemia) and other immunosuppressants.
5. PathophysiologyAfter JCPyV primary infection, latency in kidney and tonsils → with immune suppression, viral NCCR rearrangement produces neurotropic variants → infection and lysis of oligodendrocytes in the brain → demyelination → multifocal white matter lesions.
6. SymptomsSubacute progressive focal neurologic deficits: hemiparesis, visual field defects, language disorders, cerebellar ataxia, cognitive decline. Fever and headache are uncommon. Varies with lesion location (cerebellar, hemispheric, brainstem types, etc.).
7. SignsMRI: T2/FLAIR hyperintense multifocal white matter lesions (no or minimal contrast enhancement). CSF: positive JCPyV DNA PCR (specificity >95%, sensitivity 70–90%). Brain biopsy: viral inclusions in oligodendrocytes, demyelination triad.
8. ScreeningRegular screening for anti-JCPyV antibodies (STRATIFY JCV test) before and during natalizumab treatment. In antibody-positive, high-titer patients, risk stratification followed by MRI monitoring. Tracking CD4 counts in HIV patients also serves an indirect screening role.
9. DiagnosisDiagnostic criteria: characteristic MRI + positive CSF JCPyV PCR (definitive diagnosis). If CSF PCR is negative and clinical suspicion persists, brain biopsy (immunohistochemistry, electron microscopy, PCR). Differentiation from immune reconstitution inflammatory syndrome (IRIS) is important.
10. TreatmentNo curative antiviral agent. Key treatment: immune recovery (starting/optimizing ART in HIV patients, plasmapheresis after stopping natalizumab, reducing immunosuppressants). Short-term corticosteroids to control IRIS. Supportive care.
11. PrognosisHIV-associated PML: 1-year survival about 50–60% in the ART era, with stabilization in some after ART. Natalizumab-associated PML: 1-year mortality about 20%, with moderate to severe disability in 70% of survivors. Immune reconstitution is the most important prognostic factor.
12. PreventionHIV patients: maintain CD4 count ≥200/μL (ART). Natalizumab: regular measurement of anti-JCPyV antibody index; consider switching therapy in high-risk groups. Education on early recognition of PML in all immunosuppressed patients.
13. ReferencesCortese I, Reich DS, Nath A. Progressive Multifocal Leukoencephalopathy and the Spectrum of JC Virus-Related Disease. Nat Rev Neurol. 2021 … and 9 other papers

1. History

Progressive multifocal leukoencephalopathy (PML) was first described in 1958 by the American neurologists Karl-Olov Åström, Marian Mancall, and Edward Richardson, who reported unusual multifocal white matter demyelinating lesions in 3 patients with leukemia or Hodgkin lymphoma. They pointed out that this was a previously unknown neurologic disease and, based on the pathologic findings, proposed the name 'progressive multifocal leukoencephalopathy'.

The first clue to a viral etiology came in 1965, when Gabriele Zu Rhein found papillomavirus-like viral particles (icosahedral nucleocapsids 28–33 nm in diameter) in PML lesions by electron microscopy. Subsequently, in 1971, Padgett et al. succeeded in isolating and culturing the virus from the brain tissue of a PML patient in human fetal glial cell culture, and named it JC virus (JCPyV, John Cunningham polyomavirus) after the initials of the patient who provided the virus. The JC virus was identified as a double-stranded DNA virus belonging to the family Polyomaviridae.

Until the AIDS epidemic of the 1980s, PML was an extremely rare disease reported sporadically in patients with hematologic malignancies. However, in the 1980s–90s, when the number of HIV/AIDS patients increased explosively, PML also became established as one of the AIDS-defining illnesses and rose sharply. Before the introduction of ART (before 1996), the prevalence of PML in AIDS patients was about 5%, which led to an explosive increase in PML research. With the introduction of highly active antiretroviral therapy (HAART) in 1996, the incidence of PML in AIDS patients decreased by about 80%, but a new complication, immune reconstitution inflammatory syndrome (IRIS), emerged.

In 2005–2006, cases of PML in patients treated with natalizumab (Tysabri), a drug for multiple sclerosis, were reported and caused great shock; subsequent reports of PML associated with several biologic immunosuppressants (ofatumumab, ocrelizumab, rituximab, etc.) renewed attention to the clinical importance of PML. Natalizumab-associated PML led to the development of a risk stratification strategy based on measurement of JCPyV antibodies.


2. Causes

The causative pathogen of PML is JC polyomavirus (JCPyV). JCPyV is a double-stranded circular DNA virus with a genome of about 5.1 kb, composed of a regulatory region (NCCR, Non-Coding Control Region), an early region (encoding LTAg, STAg, T'Ag, etc.), and a late region (encoding VP1, VP2, VP3, and agnoprotein).

In the general adult population, the seropositivity rate for JCPyV is 50–70%, and primary infection is presumed to occur in childhood as an asymptomatic or mild upper respiratory tract infection. After primary infection, the virus remains latent in renal tubular cells and tonsillar B lymphocytes. JCPyV DNA is detected in the urine of about 20–40% of healthy individuals, which indicates that the virus intermittently replicates and is shed from the kidney in the latent infection state.

PML occurs when JCPyV reactivates from the latent infection state under severely impaired cell-mediated immunity. The reactivated virus is thought to reach the central nervous system through the bloodstream, or JCPyV-infected B lymphocytes are thought to migrate to the brain and deliver the virus. In the brain, JCPyV mainly infects oligodendrocytes and astrocytes, and selective destruction of oligodendrocytes causes demyelination.

The main predisposing conditions for PML are as follows: ① HIV/AIDS (CD4+ T cells <200/μL), ② hematologic malignancies (non-Hodgkin lymphoma, CLL, multiple myeloma, leukemia), ③ immunosuppressant therapy after solid organ transplantation, ④ natalizumab (a drug for multiple sclerosis) — blocks T-cell trafficking into the brain, weakening JCPyV immune surveillance, ⑤ other biologic agents (rituximab, ofatumumab, ocrelizumab, vedolizumab, etc.), ⑥ long-term immunosuppressive treatment for autoimmune diseases.


3. Genetics

PML is not a genetic disease caused by a single-gene abnormality. However, there are studies indicating that the host's genetic background influences immune control of JCPyV and susceptibility to PML. The most notable study concerns the association between HLA (human leukocyte antigen) type and JCPyV-specific CD8+ T-cell responses. The HLA-A*02:01 allele is associated with a strong cytotoxic T-cell response to JCPyV VP1 protein peptides, and there are studies showing that JCPyV is controlled more efficiently in individuals with this genotype.

Conversely, in individuals lacking specific HLA types, the cellular immune response to JCPyV may be weak, raising the risk of PML. There are also reports that immune response–related genes (e.g., costimulatory molecules involved in CD4+ T-cell activation, cytokine receptor gene polymorphisms) influence control of JCPyV.

In terms of viral genetics, rearrangement of the JCPyV NCCR (regulatory region) is known as the key viral factor in the development of PML. The archetype JCPyV in the latent infection state has an NCCR of simple structure, but when reactivated under immunosuppression, the NCCR is converted into a rearranged form through deletion, insertion, and rearrangement. This rearranged JCPyV acquires neurotropism, replicating more efficiently in the brain through neuron-specific transcription factors (e.g., NF-1X, YB-1). Conversely, the archetype is mainly detected in the kidney and urine, so there is a clear distinction between detection of JCPyV in urine and replication of rearranged JCPyV in the brain.


4. General epidemiology

The incidence of PML varies greatly with the type and degree of the underlying immunosuppression. In AIDS patients in the pre-ART era (before 1996), the prevalence of PML was about 4–5%, making it the third most common opportunistic neurologic disease among AIDS-defining illnesses. After ART became widespread, the incidence of HIV-associated PML decreased by about 80%, but it has not been completely eradicated. At present, the incidence of PML in HIV/AIDS patients remains significant in cases of ART nonadherence, late diagnosis, treatment-resistant HIV, and so on.

The incidence of natalizumab-associated PML varies greatly with treatment duration, prior immunosuppressant use, and anti-JCPyV antibody titer (index ≥0.9). In antibody-negative patients, the risk of PML is less than 1/10,000, but with antibody positivity, high titer (index ≥1.5), prior immunosuppressant use, and natalizumab treatment longer than 24 months, the risk increases to 1/50. In hematologic malignancy–associated PML (non-Hodgkin lymphoma, CLL), the incidence is estimated at 0.07–0.45%.

In Korea, PML was very rare before the surge of HIV/AIDS, but since the 2000s, case reports have continued with the increase in HIV-infected individuals and wider use of biologic agents. In Korean HIV/AIDS cohort data, PML is reported to account for about 1–3% of AIDS-defining illnesses and is trending sharply downward in the ART era. As domestic use of natalizumab for multiple sclerosis increases, surveillance for associated PML is becoming important.


5. Pathophysiology

The pathophysiology of PML is explained as a stepwise process of latent infection, reactivation, and neuroinvasion of JCPyV. JCPyV primary infection occurs asymptomatically in childhood, and the virus remains latent in the archetype form in renal tubular cells and tonsillar B lymphocytes. During this period, CD4+ and CD8+ T cells respond specifically to JCPyV antigens and keep viral replication suppressed.

When JCPyV-specific T-cell responses are lost in an immunocompromised state, viral replication in the kidney increases and JCPyV shedding in urine rises. At the same time, JCPyV enters the bloodstream via B lymphocytes or is delivered directly to the brain through the bloodstream. In the brain, the virus acquires neurotropism through NCCR rearrangement and infects mainly oligodendrocytes, causing lytic infection. Because oligodendrocytes produce and maintain myelin in the white matter of the central nervous system, their massive destruction results in multifocal demyelination.

Natalizumab treats multiple sclerosis by blocking α4-integrin and thereby inhibiting T-lymphocyte passage across the blood-brain barrier, but at the same time it weakens immune surveillance against JCPyV in the brain and increases the risk of PML. In natalizumab-associated PML patients, depletion of JCPyV-specific T cells in the brain has been confirmed.

Immune reconstitution inflammatory syndrome (IRIS): A phenomenon in which, when immunity recovers rapidly after starting ART in HIV patients or after stopping natalizumab, an excessive inflammatory response to JCPyV in the brain occurs and PML lesions transiently worsen. PML-IRIS shows contrast enhancement, brain edema, and sudden clinical deterioration, and requires corticosteroid administration.


6. Symptoms

The clinical symptoms of PML vary depending on the location of the multifocal white matter lesions. A common feature is subacute (weeks to months) progressive focal neurologic deficits, and symptoms of infectious meningitis such as fever, headache, and neck stiffness are absent or minimal.

Motor abnormalities: The most common initial symptom, presenting as hemiparesis (weakness of one side of the upper and lower limbs) and hemiplegia. Prominent when lesions involve the internal capsule or corticospinal tract.

Visual field defects and visual abnormalities: Homonymous hemianopia occurs with occipital white matter involvement; diplopia and cortical visual disturbance may also occur.

Language disorders: Aphasia and dysarthria occur with left hemisphere involvement.

Cerebellar symptoms: With involvement of the cerebellum or cerebellar white matter, ataxia, dysarthria, and nystagmus appear, leading to inability to walk independently.

Cognitive dysfunction: With frontal white matter involvement, decreased concentration, memory impairment, and executive dysfunction progress; with extensive involvement, cognitive decline worsens to the level of dementia.

Epileptic seizures: Can occur with lesions adjacent to the cortex and are reported in about 20–25% of PML patients.

Brainstem symptoms: Rarely, cranial nerve palsy, dysphagia, and respiratory abnormalities occur. Symptoms usually worsen continuously over weeks to months, and without treatment eventually lead to a vegetative state or death.


7. Signs

MRI findings: The most important test in imaging diagnosis of PML. The characteristic finding is T2/FLAIR hyperintense lesions in the subcortical and deep white matter, with subcortical lesions involving the U-fibers (subcortical U-fiber) being characteristic. Lesions are multifocal and asymmetric, and tend to increase and coalesce over time. Initially there is no or only minimal contrast enhancement (because the inflammatory response is weak in the immunocompromised state), but with PML-IRIS contrast enhancement becomes prominent. Diffusion restriction at the lesion edge on diffusion-weighted imaging (DWI) is characteristic of active PML.

CSF examination: JCPyV DNA PCR is the key diagnostic test, with sensitivity 70–90% and specificity >95%. Even if PCR is negative, PML cannot be excluded when clinical and imaging findings are typical, and PCR can turn negative when viral load decreases after immune reconstitution. CSF cell count, protein, and glucose are usually normal or show only minor abnormalities.

Brain biopsy: Consider when CSF PCR is negative, imaging is atypical, or the diagnosis is uncertain. Histologic triad (demyelination triad): ① demyelination, ② enlarged bizarre astrocytes, ③ viral inclusions in oligodendrocytes (ground-glass or crystalline form within the nucleus). JCPyV VP1 protein is detected by immunohistochemistry, or viral DNA is confirmed by PCR.

Anti-JCPyV antibodies: Serum anti-JCPyV IgG testing (STRATIFY JCV) is used for risk stratification of natalizumab-associated PML; the higher the titer index (≥1.5), the more the risk increases.


8. Screening

Screening for PML in the general population is not performed. Risk stratification and monitoring in PML risk groups serve as the practical screening.

Patients using natalizumab: Perform anti-JCPyV IgG antibody testing (STRATIFY JCV test) before starting treatment, and remeasure at 6-month intervals thereafter. In antibody-negative patients the risk of PML is very low, but the possibility of seroconversion must be monitored. In antibody-positive, high-titer (index ≥1.5) patients, the risk rises sharply with treatment beyond 24 months, so the need to continue treatment should be carefully reassessed. Through risk stratification, high-risk patients undergo brain MRI at 3–6-month intervals, aiming for early detection of asymptomatic PML.

HIV/AIDS patients: Regular follow-up of CD4+ T-cell counts is key. Because the risk of PML rises greatly at CD4 <200/μL, maintaining ART adherence and viral suppression is the best prevention. When unexplained neurologic symptoms occur, actively consider immediate neuroimaging (MRI) and CSF JCPyV PCR.

Patients using rituximab, ocrelizumab, or other biologic agents: There are as yet no standardized screening guidelines for monitoring PML risk, but because MRI and CSF testing must be performed immediately when neurologic abnormalities occur, clinical vigilance is the key screening strategy.


9. Diagnosis

The diagnosis of PML is made by a combination of clinical findings, brain MRI, and CSF JCPyV PCR, and is confirmed by brain biopsy when necessary.

Diagnostic criteria (AAN recommended criteria): ① subacute progressive multifocal neurologic deficits arising in an immunocompromised state, ② characteristic brain MRI findings (non-enhancing T2 hyperintense white matter lesions, U-fiber involvement), ③ positive CSF JCPyV PCR — when all three are met, clinical confirmation is possible. Brain biopsy is considered when CSF PCR is negative but clinical or imaging suspicion is high, or when other diagnostic possibilities must be excluded.

In differential diagnosis, the important conditions are multiple sclerosis, brain lymphoma, HIV encephalopathy, CMV encephalitis, and toxoplasma encephalopathy. In differentiating from multiple sclerosis, differences in MRI findings help (in MS, lesions are smaller with vertical orientation and contrast enhancement is frequent). On brain MRI, PML lesions show no or minimal contrast enhancement, whereas brain lymphoma presents as a single or a few lesions with ring enhancement, which helps distinguish them.

PML-IRIS diagnosis: Consider PML-IRIS when, after starting ART or stopping natalizumab, PML lesions show contrast enhancement and worsening on MRI, CSF inflammatory cells increase, and the patient deteriorates clinically. PML-IRIS means that immune recovery is under way, but it can cause clinical worsening in the short term.


10. Treatment

There is currently no established specific antiviral treatment for PML. The core of treatment is immune restoration.

HIV-associated PML: In patients not on ART, start ART immediately; in patients already on ART, optimize viral suppression. Recovery of CD4 T cells by ART is the most effective treatment, restoring immune control of JCPyV. PML-IRIS can occur within a few weeks after starting ART, so close monitoring is needed.

Natalizumab-associated PML: Stop natalizumab immediately and perform plasmapheresis (PLEX) to rapidly clear natalizumab and quickly reverse α4-integrin blockade. This induces re-entry of CD4 T cells into the brain. Because PML-IRIS occurs frequently (about 70%) after plasmapheresis, be prepared to monitor for clinical deterioration and to administer corticosteroids (methylprednisolone) when necessary.

Other immunosuppression-associated PML: Reduce or stop immunosuppressants to the extent the underlying disease allows. In solid organ transplant patients, a balance between graft rejection and PML is needed.

Antiviral agent trials: Cidofovir, cytarabine, mefloquine, mirtazapine, and others have been tried in small studies, but clinical efficacy has not been proven. Recently, cases of PML stabilization after pembrolizumab (a PD-1 inhibitor) have been reported, and immune checkpoint inhibitors are being studied as a new treatment option through induction of PML-IRIS.

Supportive care: Anticonvulsants for seizure control, corticosteroids for brain edema (in PML-IRIS), pneumonia prevention, nutritional support, and rehabilitation are provided together.


11. Prognosis

The prognosis of PML varies greatly with the underlying immunosuppressed state and the possibility of immune recovery. Overall the prognosis is poor, but since the introduction of ART the prognosis of HIV-associated PML has improved significantly.

HIV-associated PML: In the pre-ART era, median survival was only about 2–4 months after diagnosis, but after ART 1-year survival improved to about 50–60%. When the CD4 count recovers and the CSF JCPyV load decreases after starting ART, PML may stabilize or some neurologic function may recover. About 40–60% of survivors have moderate to severe neurologic sequelae.

Natalizumab-associated PML: 1-year mortality is about 20–25%, and 70–80% of survivors are left with moderate to severe neurologic disability. Early detection (before symptoms or at a mild stage) is important for improving prognosis, so risk stratification monitoring has great clinical significance. The prognosis is worse the larger the lesions at diagnosis, with cerebellar involvement, and with greater severity of PML-IRIS.

Prognostic factors: The most important prognostic factor is the degree of immune recovery, and recovery of CD4 count and of JCPyV-specific T-cell responses is directly linked to stabilization of the PML course. Early diagnosis (at the beginning of the neurologic deficit) and prompt immune restoration measures are the key to improved prognosis. A decrease in CSF JCPyV load after treatment is an indicator of good response.


12. Prevention

There is currently no direct vaccine or pharmacologic prevention for PML. The key to prevention is preventing and minimizing the underlying immunosuppressed state and risk stratification and early detection in high-risk patients.

HIV/AIDS patients: Early initiation of ART and sustained viral suppression (plasma HIV RNA <50 copies/mL) to maintain the CD4 T-cell count at ≥200/μL, ideally ≥350/μL, is the key to PML prevention. Management of ART adherence and maintenance of optimal ART through resistance testing are needed.

Patients using natalizumab: In patients who are anti-JCPyV antibody-negative and have no prior immunosuppressant use, the risk is low, so treatment can be maintained while monitoring the antibody index every 6 months. In antibody-positive, high-titer patients, reassess risk-benefit when treatment exceeds 24 months and consider switching to alternative therapies (ocrelizumab, ofatumumab, etc.). However, PML risk monitoring is needed even after switching.

Other immunosuppressed patients: Recognize the risk of PML in patients receiving B-cell–depleting therapy such as rituximab, and perform immediate evaluation when neurologic symptoms occur. The principle is to avoid unnecessary excessive immunosuppression and to maintain the minimum level of immunosuppression required to control the underlying disease.


13. References

  1. Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17(1):37-51. DOI: 10.1038/s41582-020-00427-y. PMID: 33219338.

  2. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-1438. DOI: 10.1212/WNL.0b013e31828c2fa1. PMID: 23535493.

  3. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880. DOI: 10.1056/NEJMoa1107829. PMID: 22591293.

  4. Pavlovic D, Patera AC, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255-273. DOI: 10.1177/1756285615602832. PMID: 26600875.

  5. Muftuoglu M, Olson A, Marin D, et al. Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med. 2018;379(15):1443-1451. DOI: 10.1056/NEJMoa1801540. PMID: 30304652.

  6. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59-68. DOI: 10.3109/13550289809113482. PMID: 9531014.

  7. Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol. 2001;7(4):386-390. DOI: 10.1080/13550280152537111. PMID: 11517422.

  8. Moster ML, Bhimani A, Bhimani A. Pembrolizumab treatment of progressive multifocal leukoencephalopathy: a systematic review. J Neurol. 2023;270(5):2523-2533. DOI: 10.1007/s00415-023-11570-0. PMID: 36840790.

  9. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol. 2006;60(2):162-173. DOI: 10.1002/ana.20933. PMID: 16878015.

  10. Brändle SM, Obermeier B, Senel M, et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci USA. 2016;113(28):7864-7869 (reference for PML differentiation). DOI: 10.1073/pnas.1522730113. PMID: 27354527.